BUZZ-Traws Pharma gains on approval to begin mid-stage study of COVID antiviral
Reuters
Aug 18
BUZZ-<a href="https://laohu8.com/S/TRAW">Traws Pharma</a> gains on approval to begin mid-stage study of COVID antiviral
** Shares of Traws Pharma TRAW.O rise 4% to $1.57 premarket
** TRAW says it has received approval from the Human Research Ethics Committee to proceed with mid-stage study of its COVID-19 antiviral candidate, ratutrelvir
** Company expects to have results from the study by the end of this year
** In an early-stage study, patients only needed to take one tablet of ratutrelvir per day for 10 days compared to Pfizer's PFE.N Paxlovid, which requires multiple tablets twice daily for 5 days - TRAW
** Up to last close, TRAW shares down 83% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.